Essex Investment Management Co. LLC Takes Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Essex Investment Management Co. LLC bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 474,955 shares of the company’s stock, valued at approximately $1,610,000. Essex Investment Management Co. LLC owned 0.32% of Xeris Biopharma at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. R Squared Ltd acquired a new position in shares of Xeris Biopharma during the fourth quarter worth $42,000. Wealth Enhancement Advisory Services LLC acquired a new position in Xeris Biopharma during the 3rd quarter worth about $35,000. Raymond James Financial Inc. bought a new stake in shares of Xeris Biopharma in the 4th quarter valued at about $45,000. Quantbot Technologies LP acquired a new stake in shares of Xeris Biopharma in the third quarter valued at about $44,000. Finally, Sunpointe LLC bought a new position in shares of Xeris Biopharma during the fourth quarter worth about $71,000. 42.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on XERS shares. HC Wainwright reissued a “buy” rating and set a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Finally, Piper Sandler restated a “neutral” rating and issued a $4.00 target price (up previously from $3.00) on shares of Xeris Biopharma in a report on Friday.

Xeris Biopharma Stock Performance

Shares of XERS opened at $4.24 on Monday. The firm has a market cap of $632.10 million, a PE ratio of -9.42 and a beta of 2.32. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $4.50. The business’s 50 day moving average price is $3.57 and its two-hundred day moving average price is $3.26.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.